Nadifloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Nadifloxacin is a topical fluoroquinolone used in the treatment of acne and topical bacterial skin infections.

Generic Name
Nadifloxacin
DrugBank Accession Number
DB12447
Background

Nadifloxacin has been used in trials studying the treatment of Acne Vulgaris.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 360.385
Monoisotopic: 360.148535327
Chemical Formula
C19H21FN2O4
Synonyms
  • Nadifloxacin
  • Nadifloxacino

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Treatment ofAcne vulgaris•••••••••••••••••
Treatment ofSuperficial skin infections•••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
EstetrolThe therapeutic efficacy of Estetrol can be decreased when used in combination with Nadifloxacin.
Fecal microbiotaThe therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Nadifloxacin.
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Nadifloxacin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
D10AF05 — Nadifloxacin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Aryl fluorides / Benzenoids / Piperidines
show 11 more
Substituents
Alcohol / Amine / Amino acid / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolone antibiotic, hydroxypiperidine, pyridoquinoline, heteroarylpiperidine (CHEBI:31889)
Affected organisms
Not Available

Chemical Identifiers

UNII
6CL9Y5YZEQ
CAS number
124858-35-1
InChI Key
JYJTVFIEFKZWCJ-UHFFFAOYSA-N
InChI
InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)
IUPAC Name
7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.0⁵,¹³]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
SMILES
CC1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N1CCC(O)CC1

References

General References
  1. TITCK Product Information: Nadixa (nadifloxacin) topical cream [Link]
PubChem Compound
4410
PubChem Substance
347828688
ChemSpider
4257
BindingDB
50475222
ChEBI
31889
ChEMBL
CHEMBL363449
Wikipedia
Nadifloxacin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAcne Vulgaris1
3Unknown StatusTreatmentAcne Vulgaris1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CreamCutaneous1.000 g
CreamTopical1 %
CreamTopical
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.632 mg/mLALOGPS
logP0.87ALOGPS
logP1.84Chemaxon
logS-2.8ALOGPS
pKa (Strongest Acidic)6.13Chemaxon
pKa (Strongest Basic)0.44Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area81.08 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity96.03 m3·mol-1Chemaxon
Polarizability36.53 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03dl-0019000000-5a82af9804b7e75eddaa
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ox-0009000000-4248a9014db435811319
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-052b-0069000000-178ad99fd3e6d0479a49
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0009000000-f6c0d1d64a9a2f480686
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0002-0097000000-822ce0adf783d33f1536
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-006x-0069000000-c20a341cc4745edd7560
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-02t9-0095000000-63885878a1624c9f019c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-186.80843
predicted
DeepCCS 1.0 (2019)
[M+H]+189.54161
predicted
DeepCCS 1.0 (2019)
[M+Na]+196.70277
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:25 / Updated at May 27, 2021 02:58